Carcinoid Tumor Market Report 2026

Carcinoid Tumor Market Overview

• Carcinoid Tumor market size has reached to $1.77 billion in 2025 • Expected to grow to $2.88 billion in 2030 at a compound annual growth rate (CAGR) of 10.1% • Growth Driver: Impact Of Obesity On The Growth Of The Market • Market Trend: Advancements In Neuroendocrine Tumor Detection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Carcinoid Tumor Market?

A carcinoid tumor is a rare, slow-growing type of neuroendocrine tumor that typically arises in the gastrointestinal tract or lungs. It originates from enterochromaffin cells, which produce and release hormones such as serotonin. Symptoms may vary depending on the tumor's location and whether it secretes hormones, potentially causing carcinoid syndrome. The main disease types of carcinoid tumors are gastrointestinal neuroendocrine tumors (GI NETs), pancreatic neuroendocrine tumors, lung neuroendocrine tumors, and other disease types. Gastrointestinal neuroendocrine tumors (GI NETs) are abnormal growths originating from neuroendocrine cells in the digestive system, with carcinoid tumors being a common, slow-growing subtype. Treatments for these tumors include octreotide, lanreotide, telotristat ethyl, capecitabine (Xeloda), 5-fluorouracil (5-FU), doxorubicin (Adriamycin), etoposide (VP-16), dacarbazine (DTIC), streptozocin, and other therapies, administered via oral, parenteral, and others. These treatments are distributed through online and offline channels and are used by various end-users, including hospitals and clinics, academic institutions, and research organizations.

What Is The Carcinoid Tumor Market Growth Forecast?

The carcinoid tumor market size is expected to see rapid growth in the next few years. It will grow to $2.88 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing development of novel targeted therapies, rising investments in rare cancer treatment research, expansion of precision oncology approaches, growing adoption of personalized treatment plans, increasing focus on quality-of-life outcomes. Major trends in the forecast period include increasing adoption of targeted neuroendocrine tumor therapies, rising use of combination drug regimens, growing focus on early tumor diagnosis, expansion of specialized oncology treatment centers, enhanced emphasis on long-term disease management.

Global Carcinoid Tumor Market Segmentation

1) By Disease Type: Gastrointestinal Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Lung Neuroendocrine Tumor, Other Disease Types 2) By Treatment: Octreotide, Lanreotide, Telotristat ethyl, Capecitabine (Xeloda), 5-Fluorouracil (5-FU), Doxorubicin (Adriamycin), Etoposide (VP-16), Dacarbazine (DTIC), Streptozocin, Other Treatments 3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 4) By End User: Hospital And Clinics, Academic Institutions, Research Organizations Subsegments: 1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors, Appendiceal Neuroendocrine Tumors 2) By Pancreatic Neuroendocrine Tumor: Insulinoma, Non-insulinoma, Glucagonoma 3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors, Atypical Carcinoid Tumors 4) By Other Disease Types: Thymic Neuroendocrine Tumors, Ovarian Neuroendocrine Tumors

What Is The Driver Of The Carcinoid Tumor Market?

The growing obese population is expected to propel the growth of the carcinoid tumor market going forward. The obese population refers to individuals whose body mass index (BMI) is 30 or higher, indicating excessive body fat. The growing obese population is attributed to factors such as poor dietary habits, lack of physical activity, sedentary lifestyles, and increased consumption of processed and high-calorie foods. Obesity contributes to carcinoid tumor development by promoting chronic inflammation, insulin resistance, and increased secretion of growth factors that support tumor growth. For instance, in May 2025, according to the Office for Health Improvement and Disparities (OHID), a UK-governmentagency, in 2023–2024, about 64.5% of adults (18+) in England were estimated to be either overweight or living with obesity, this is slightly up from 64.0% in the previous period (2022–2023). Therefore, the growing obese population is driving the growth of the carcinoid tumor industry.

Key Players In The Global Carcinoid Tumor Market

Major companies operating in the carcinoid tumor market are Novartis AG, Ipsen SA, Pfizer Inc, Merck & Co Inc, F Hoffmann-La Roche Ltd, Eli Lilly and Company, Sanofi SA, AstraZeneca PLC, Bristol Myers Squibb, Amgen Inc, Takeda Pharmaceutical Company, Bayer AG, Exelixis Inc, Lexicon Pharmaceuticals Inc, HUTCHMED, Crinetics Pharmaceuticals, Clovis Oncology, Taiho Pharmaceutical, Eisai Co Ltd, Teva Pharmaceutical Industries

Global Carcinoid Tumor Market Trends and Insights

Major companies operating in the carcinoid tumor market are focusing on advancements in diagnostic technologies, such as the fully automated chromogranin A test, to enhance early detection and improve treatment outcomes. The automated chromogranin A (CgA) test refers to a fully automated diagnostic tool used to measure levels of chromogranin A, a biomarker commonly associated with neuroendocrine tumors, including carcinoid tumors. For instance, in October 2023, Thermo Fisher Scientific Inc., a US-based biotechnology research company, received FDA clearance for its Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay. This marks the first FDA-approved Chromogranin A (CgA) test and the only automated immunoassay globally for monitoring tumor progression in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. Designed to measure CgA concentration in human serum, the assay enables laboratories and cancer centers to track tumor growth and assess treatment efficacy. By replacing manual laboratory-developed tests, it enhances lab efficiency and ensures clearer result interpretation. The test operates on the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS random-access immunoassay analyzer, utilizing TRACE technology to deliver precise results in under 30 minutes.

What Are Latest Mergers And Acquisitions In The Carcinoid Tumor Market?

In March 2024, Merck, a US-based multinational pharmaceutical company, acquired Harpoon Therapeutics, Inc., for an undisclosed amount. With this acquisition, Merck aims to strengthen its oncology pipeline, accelerate the development of innovative immuno-oncology therapies, expand its therapeutic portfolio, and enhance its capabilities in targeted cancer treatments. Harpoon Therapeutics, Inc., is a US-based biopharmaceutical company specializing in the development of next-generation T-cell engagers for the treatment of solid tumors.

Regional Outlook

North America was the largest region in the carcinoid tumor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Carcinoid Tumor Market?

The carcinoid tumor market consists of revenues earned by entities by providing services such as pharmaceutical treatment, radiation therapy, diagnostic services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The carcinoid tumor market also includes sales of diagnostic tools, pharmaceuticals, chemotherapy agents, radiopharmaceuticals, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Carcinoid Tumor Market Report 2026?

The carcinoid tumor market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the carcinoid tumor industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.